New and recently funded Medical Startups
1
Country: USA | Funding: $971M
Zipline designs, manufactures, and operates drones to deliver vital medical products.
Zipline designs, manufactures, and operates drones to deliver vital medical products.
2
Country: UK | Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
3
Country: UK | Funding: $10M
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
4
Country: USA | Funding: $354M
Function Health is a continuous health checkup service. For $365/year, users schedule and undergo over 100 lab tests (including advanced add-ons like MRIs), receive detailed clinical health assessments and early detection of serious illnesses. No insurance needed. Diagnostics are performed by human experts using a medical artificial intelligence model. The company also offers its users a chatbot (an AI health manager) that can answer questions based on their health data and use previous lab results, doctor notes, and imaging to provide personalized recommendations. The platform is HIPAA-compliant, fully encrypts user data, and never sells personal information.
Function Health is a continuous health checkup service. For $365/year, users schedule and undergo over 100 lab tests (including advanced add-ons like MRIs), receive detailed clinical health assessments and early detection of serious illnesses. No insurance needed. Diagnostics are performed by human experts using a medical artificial intelligence model. The company also offers its users a chatbot (an AI health manager) that can answer questions based on their health data and use previous lab results, doctor notes, and imaging to provide personalized recommendations. The platform is HIPAA-compliant, fully encrypts user data, and never sells personal information.
5
Country: USA | Funding: $13M
Onepot.ai automates synthesis of small molecules from basic building blocks using chemical reactions. The company operates a small molecule synthesis lab, POT-1 and an LLM, which learns from all successful and unsuccessful experiments to predict what works and what doesn't when creating compounds and suggests potential molecules. As a result, Onepot has a catalog of molecules it can manufacture. Clients (biotech and pharma companies) select the desired compounds and Onepot's technology then synthesizes these molecules and ships them to the client for use in their experiments. They ship physical products either as dry compounds or as solutions in tablets or vials.
Onepot.ai automates synthesis of small molecules from basic building blocks using chemical reactions. The company operates a small molecule synthesis lab, POT-1 and an LLM, which learns from all successful and unsuccessful experiments to predict what works and what doesn't when creating compounds and suggests potential molecules. As a result, Onepot has a catalog of molecules it can manufacture. Clients (biotech and pharma companies) select the desired compounds and Onepot's technology then synthesizes these molecules and ships them to the client for use in their experiments. They ship physical products either as dry compounds or as solutions in tablets or vials.
6
Country: USA | Funding: $1.3B
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
7
Country: USA
AAA Biotech (also known as AAA Bio or AAABio) is constantly working to expand its capacity to provide antibodies, recombinant proteins and ELISA kits targeting a wide range of proteins. The majority of AAA Biotech’s antibodies are highly validated and can be use in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. The company has antibodies available for rare species, in multiple conjugated forms or recombinant antibodies.
AAA Biotech (also known as AAA Bio or AAABio) is constantly working to expand its capacity to provide antibodies, recombinant proteins and ELISA kits targeting a wide range of proteins. The majority of AAA Biotech’s antibodies are highly validated and can be use in multiple applications such as ELISA, FC, ICC, IF, IHC, IP, WB, etc. The company has antibodies available for rare species, in multiple conjugated forms or recombinant antibodies.
8
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
9
Country: UK | Funding: $188M
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
10
Country: Denmark | Funding: $249.6M
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
